Company news
Amgen Inc. news in 2019
Amgen Inc.'s news releases, calls and decks from 2019, newest first.
Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
December 18, 2019
European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
December 10, 2019
Amgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub
December 8, 2019
FDA Approves Amgen's AVSOLA(TM) (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
December 5, 2019
Amgen Announces Data Being Presented At ASH 2019
December 1, 2019
Amgen Completes Acquisition Of Otezla® (apremilast)
November 20, 2019
Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack
November 15, 2019
Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors
November 14, 2019
Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China
October 30, 2019
Amgen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Corporation
October 22, 2019
Amgen Announces 2019 Fourth Quarter Dividend
October 21, 2019
EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
October 16, 2019
Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh
October 8, 2019
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019
September 26, 2019
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
September 23, 2019
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019
September 7, 2019
Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer
September 3, 2019
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
August 25, 2019
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
August 21, 2019
Amgen Wins Patent Case On Enbrel® (etanercept)
August 8, 2019
Amgen Announces 2019 Third Quarter Dividend
August 1, 2019
Amgen And Allergan's MVASI(TM) (bevacizumab-awwb) And KANJINTI(TM) (trastuzumab-anns) Now Available In The United States
July 17, 2019
Amgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer
July 7, 2019
Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
June 24, 2019
Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership
June 18, 2019
Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
June 14, 2019
FDA Approves Amgen And Allergan's KANJINTI(TM) (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
June 12, 2019
Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution
June 11, 2019
Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
June 6, 2019
Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019
June 2, 2019
Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
May 28, 2019
Amgen Joins With Community Oncology Networks For New Research Collaboration
May 27, 2019
Amgen announces a recommended public cash offer to the shareholders of Nuevolution
May 20, 2019
Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting
May 1, 2019
Amgen Announces Webcast of 2019 First Quarter Financial Results
April 24, 2019
Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
April 16, 2019